We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

57 hedge funds and large institutions have $313M invested in Arcus Biosciences in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

14% more capital invested

Capital invested by funds: $274M → $313M (+$38.7M)

0.09% more ownership

Funds ownership: 50.38% → 50.47% (+0.09%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less funds holding

Funds holding: 64 → 57 (-7)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
57
Holders Change
-7
Holders Change %
-10.94%
% of All Funds
1.3%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
4
Increased
27
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$2.75M
2
Millennium Management
Millennium Management
New York
+$1.45M
3
BlackRock
BlackRock
New York
+$1.28M
4
BI
BVF Inc
California
+$1.26M
5
PIM
Platinum Investment Management
Australia
+$548K

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.26M
2
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$2.25M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.07M
4
LCM
Laurion Capital Management
New York
-$734K
5
PHS
PFM Health Sciences
California
-$567K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$708K +$137K +10,706 +27%
VEA
27
Virtus ETF Advisers
New York
$400K -$269K -21,065 -42%
TD Asset Management
28
TD Asset Management
Ontario, Canada
$317K -$82.9K -6,497 -22%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$295K +$65.5K +5,138 +32%
Deutsche Bank
30
Deutsche Bank
Germany
$293K +$140K +10,986 +109%
LFM
31
Lumina Fund Management
New York
$279K +$38.3K +3,000 +18%
Goldman Sachs
32
Goldman Sachs
New York
$254K -$136K -10,638 -37%
Marshall Wace
33
Marshall Wace
United Kingdom
$247K +$226K +17,723 New
Morgan Stanley
34
Morgan Stanley
New York
$220K +$48.5K +3,801 +32%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$196K +$78.1K +6,125 +77%
TA
36
Teachers Advisors
New York
$178K +$163K +12,770 New
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$153K – – –
Wells Fargo
38
Wells Fargo
California
$142K +$4.46K +350 +4%
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$88K – – –
AIG
40
American International Group
New York
$86K +$35.6K +2,794 +83%
JC
41
JBF Capital
Colorado
$80K -$300K -23,537 -80%
Citigroup
42
Citigroup
New York
$78K +$22.4K +1,757 +46%
Barclays
43
Barclays
United Kingdom
$78K +$30.2K +2,371 +73%
PIM
44
Partner Investment Management
California
$72K -$1.22K -96 -2%
Federated Hermes
45
Federated Hermes
Pennsylvania
$55K +$50.3K +3,941 New
Bank of America
46
Bank of America
North Carolina
$36K +$24.1K +1,891 +278%
UBS Group
47
UBS Group
Switzerland
$32K +$21.3K +1,673 +277%
US Bancorp
48
US Bancorp
Minnesota
$30K +$27.1K +2,126 New
Legal & General Group
49
Legal & General Group
United Kingdom
$20K +$8.3K +651 +85%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$19K +$17.1K +1,342 +6,710%
1
2
3

RCUS Hedge Fund Activity: Q3 2018 in Review

57 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2018, worth a combined $313M — up 14% from $274M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of RCUS and 4 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 27 added.

The largest buyer was JP Morgan Chase, adding an estimated $2.75M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.26M.

  • 57 institutional investors held Arcus Biosciences (RCUS) as of Q3 2018, down from 64 in Q2 2018.
  • Funds reported $313M of Arcus Biosciences stock for Q3 2018, up 14% quarter-over-quarter.
  • 4 funds opened new Arcus Biosciences positions in Q3 2018 and 11 closed out, a net change of -7 holders.
  • The largest Arcus Biosciences buyer in Q3 2018 was JP Morgan Chase, an estimated $2.75M added.
  • The largest Arcus Biosciences seller in Q3 2018 was T. Rowe Price Associates, an estimated $3.26M sold.

Based on aggregated 13F filings for Q3 2018.